The FDA has granted Emergency Use Authorization for BioGX’s molecular diagnostic test the detects the presence of SARS-CoV-2, the virus causing COVID-19.
The test is performed on Becton, Dickinson and Company’s (NYSE:BDX) automated BD MAX System that can process 24 samples at a time with results generated in under three hours.
https://seekingalpha.com/news/3558124-fda-oks-emergency-use-of-becton-dickinson-biogx-coronavirus-test
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.